Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis

Medicine and Dentistry

• Diseases 100%
• Patient 100%
• Health Care Cost 83%
• Kidney Graft 66%
• Outpatient 66%
• Prophylaxis 50%
• Graft Rejection 33%
• Life 33%
• Cytomegalovirus Antibody 33%
• Follow up 16%
• Vaccine 16%
• High Risk Population 16%
• Immunoglobulin 16%
• Low Risk Population 16%
• Aciclovir 16%
• Mortality 16%
• Kidney 16%

Nursing and Health Professions

• Diseases 100%
• Kidney Graft 66%
• Donor 66%
• Cost Effectiveness Analysis 50%
• Prophylaxis 50%
• Dialysis 33%
• Graft Rejection 33%
• Follow up 16%
• Hospitalization 16%
• Vaccine Efficacy 16%
• High Risk Population 16%
• Immunoglobulin 16%
• Aciclovir 16%
• Mortality 16%
• Low Risk Population 16%

Immunology and Microbiology

• Transplantation 66%
• Transplant Rejection 33%
• Dialysis 33%
• Cytomegalovirus Antibody 33%
• Life 33%
• Intravenous Immunoglobulin 16%
• Vaccine Efficacy 16%
• High Risk Population 16%
• Mortality 16%
• Kidney 16%
• Low Risk Population 16%